Exagen Return On Equity vs. Shares Owned By Insiders
| XGN Stock | USD 3.84 0.10 2.54% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter (1.04) | Current Value (1.10) | Quarterly Volatility 8.15308347 |
For Exagen profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Exagen to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Exagen Inc utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Exagen's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Exagen Inc over time as well as its relative position and ranking within its peers.
Exagen |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share 3.163 | Quarterly Revenue Growth 0.066 | Return On Assets (0.17) | Return On Equity (0.70) |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Exagen Inc Shares Owned By Insiders vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Exagen's current stock value. Our valuation model uses many indicators to compare Exagen value to that of its competitors to determine the firm's financial worth. Exagen Inc is rated below average in return on equity category among its peers. It is rated fourth in shares owned by insiders category among its peers . At this time, Exagen's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Exagen's earnings, one of the primary drivers of an investment's value.Exagen Shares Owned By Insiders vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Exagen |
| = | -0.7 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Exagen |
| = | 29.74 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Exagen Shares Owned By Insiders Comparison
Exagen is currently under evaluation in shares owned by insiders category among its peers.
Exagen Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Exagen, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Exagen will eventually generate negative long term returns. The profitability progress is the general direction of Exagen's change in net profit over the period of time. It can combine multiple indicators of Exagen, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -22.8 M | -24 M | |
| Income Before Tax | -23.7 M | -24.8 M | |
| Total Other Income Expense Net | -819 K | -860 K | |
| Net Loss | -23.7 M | -24.9 M | |
| Income Tax Expense | 33 K | 34.6 K | |
| Interest Income | 1.5 M | 989.2 K | |
| Net Loss | -42.6 M | -40.5 M | |
| Net Loss | -32.5 M | -34.1 M | |
| Non Operating Income Net Other | 18.4 K | 19.3 K | |
| Net Interest Income | -1.6 M | -1.6 M | |
| Change To Netincome | 13.6 M | 14.3 M | |
| Net Loss | (1.34) | (1.41) | |
| Income Quality | 0.61 | 0.81 | |
| Net Income Per E B T | 1.00 | 1.10 |
Exagen Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Exagen. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Exagen position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Exagen's important profitability drivers and their relationship over time.
Use Exagen in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exagen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exagen will appreciate offsetting losses from the drop in the long position's value.Exagen Pair Trading
Exagen Inc Pair Trading Analysis
The ability to find closely correlated positions to Exagen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exagen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exagen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exagen Inc to buy it.
The correlation of Exagen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exagen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exagen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Exagen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Exagen position
In addition to having Exagen in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Disruptive Technologies Thematic Idea Now
Disruptive Technologies
New or established technology companies and funds across multiple sectors that are involved in development or marketing of products or services that experience disruptive trends and that are at the forefront of discussions on Wall Street. The Disruptive Technologies theme has 64 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Disruptive Technologies Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Current Watchlist. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
To fully project Exagen's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Exagen Inc at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Exagen's income statement, its balance sheet, and the statement of cash flows.